Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 916

1.

Advances in Imaging: Brain Tumors to Alzheimer's Disease.

Patil R, Koronyo Y, Ljubimov AV, Salumbides B, Mamelak A, Gangalum PR, Ding H, Portilla-Arias J, Holler E, Butte P, Koronyo-Hamaoui M, Ljubimova JY, Black KL.

Bangk Med J. 2015 Sep;10:83-97.

PMID:
29142857
2.

Cortical Iron Reflects Severity of Alzheimer's Disease.

van Duijn S, Bulk M, van Duinen SG, Nabuurs RJA, van Buchem MA, van der Weerd L, Natté R.

J Alzheimers Dis. 2017;60(4):1533-1545. doi: 10.3233/JAD-161143.

3.

The emerging role of PET imaging in dementia.

Iaccarino L, Sala A, Caminiti SP, Perani D.

F1000Res. 2017 Oct 12;6:1830. doi: 10.12688/f1000research.11603.1. eCollection 2017. Review.

4.

Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB study.

Landen JW, Andreasen N, Cronenberger CL, Schwartz PF, Börjesson-Hanson A, Östlund H, Sattler CA, Binneman B, Bednar MM.

Alzheimers Dement (N Y). 2017 Jun 8;3(3):393-401. doi: 10.1016/j.trci.2017.05.003. eCollection 2017 Sep.

5.

Targeting butyrylcholinesterase for preclinical single photon emission computed tomography (SPECT) imaging of Alzheimer's disease.

DeBay DR, Reid GA, Pottie IR, Martin E, Bowen CV, Darvesh S.

Alzheimers Dement (N Y). 2017 Feb 24;3(2):166-176. doi: 10.1016/j.trci.2017.01.005. eCollection 2017 Jun.

6.

2-(4'-Aminophenyl)benzothiazole Labeled with 99mTc-Cyclopentadienyl for Imaging β-Amyloid Plaques.

Kiritsis C, Mavroidi B, Shegani A, Palamaris L, Loudos G, Sagnou M, Pirmettis I, Papadopoulos M, Pelecanou M.

ACS Med Chem Lett. 2017 Sep 18;8(10):1089-1092. doi: 10.1021/acsmedchemlett.7b00294. eCollection 2017 Oct 12.

PMID:
29057056
7.

Partial volume correction for PET quantification and its impact on brain network in Alzheimer's disease.

Yang J, Hu C, Guo N, Dutta J, Vaina LM, Johnson KA, Sepulcre J, Fakhri GE, Li Q.

Sci Rep. 2017 Oct 12;7(1):13035. doi: 10.1038/s41598-017-13339-7.

8.

Subjective cognitive decline and β-amyloid burden predict cognitive change in healthy elderly.

Vogel JW, Varga Doležalová M, La Joie R, Marks SM, Schwimmer HD, Landau SM, Jagust WJ.

Neurology. 2017 Nov 7;89(19):2002-2009. doi: 10.1212/WNL.0000000000004627. Epub 2017 Oct 6.

PMID:
28986416
9.

Iterative Image Processing for Early Diagnostic of Beta-Amyloid Plaque Deposition in Pre-Clinical Alzheimer's Disease Studies.

Slavine NV, Kulkarni PV, McColl RW.

J Appl Bioinforma Comput Biol. 2017 Aug;6(2). pii: 134. doi: 10.4172/2329-9533.1000134. Epub 2017 May 31.

10.

Comparison of [18F]Flutemetamol and [11C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals.

Lowe VJ, Lundt E, Knopman D, Senjem ML, Gunter JL, Schwarz CG, Kemp BJ, Jack CR Jr, Petersen RC.

Neuroimage Clin. 2017 Aug 14;16:295-302. doi: 10.1016/j.nicl.2017.08.011. eCollection 2017.

11.

A Case Report of a 37-Year-Old Alzheimer's Disease Patient with Prominent Striatum Amyloid Retention.

Um YH, Choi WH, Jung WS, Park YH, Lee CU, Lim HK.

Psychiatry Investig. 2017 Jul;14(4):521-524. doi: 10.4306/pi.2017.14.4.521. Epub 2017 Jul 11.

12.

Small-molecule PET Tracers for Imaging Proteinopathies.

Mathis CA, Lopresti BJ, Ikonomovic MD, Klunk WE.

Semin Nucl Med. 2017 Sep;47(5):553-575. doi: 10.1053/j.semnuclmed.2017.06.003. Epub 2017 Jul 13. Review.

PMID:
28826526
13.

Evaluation of 64Cu-Based Radiopharmaceuticals that Target Aβ Peptide Aggregates as Diagnostic Tools for Alzheimer's Disease.

Bandara N, Sharma AK, Krieger S, Schultz JW, Han BH, Rogers BE, Mirica LM.

J Am Chem Soc. 2017 Sep 13;139(36):12550-12558. doi: 10.1021/jacs.7b05937. Epub 2017 Aug 29.

14.

Associations of thyroid hormone serum levels with in-vivo Alzheimer's disease pathologies.

Choi HJ, Byun MS, Yi D, Sohn BK, Lee JH, Lee JY, Kim YK, Lee DY; KBASE Research Group.

Alzheimers Res Ther. 2017 Aug 17;9(1):64. doi: 10.1186/s13195-017-0291-5.

15.

Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer's disease.

Koronyo Y, Biggs D, Barron E, Boyer DS, Pearlman JA, Au WJ, Kile SJ, Blanco A, Fuchs DT, Ashfaq A, Frautschy S, Cole GM, Miller CA, Hinton DR, Verdooner SR, Black KL, Koronyo-Hamaoui M.

JCI Insight. 2017 Aug 17;2(16). pii: 93621. doi: 10.1172/jci.insight.93621. [Epub ahead of print]

16.

PET Tau and Amyloid-β Burden in Mild Alzheimer's Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers.

Koychev I, Gunn RN, Firouzian A, Lawson J, Zamboni G, Ridha B, Sahakian BJ, Rowe JB, Thomas A, Rochester L, Ffytche D, Howard R, Zetterberg H, MacKay C, Lovestone S; Deep and Frequent Phenotyping study team (.

J Alzheimers Dis. 2017;60(1):283-293. doi: 10.3233/JAD-170129.

17.

Multi-Kernel Learning with Dartel Improves Combined MRI-PET Classification of Alzheimer's Disease in AIBL Data: Group and Individual Analyses.

Youssofzadeh V, McGuinness B, Maguire LP, Wong-Lin K.

Front Hum Neurosci. 2017 Jul 25;11:380. doi: 10.3389/fnhum.2017.00380. eCollection 2017. Erratum in: Front Hum Neurosci. 2017 Sep 08;11:457.

18.

Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau.

Josephs KA.

Mayo Clin Proc. 2017 Aug;92(8):1291-1303. doi: 10.1016/j.mayocp.2017.04.016. Review.

PMID:
28778262
19.

A Systematic Review of Longitudinal Studies Which Measure Alzheimer's Disease Biomarkers.

Lawrence E, Vegvari C, Ower A, Hadjichrysanthou C, De Wolf F, Anderson RM.

J Alzheimers Dis. 2017;59(4):1359-1379. doi: 10.3233/JAD-170261.

20.

Editorial Introduction to the Special Issue from the International Symposium on Biomarkers for Alzheimer's Disease and Related Disorders.

Sabbagh MN.

Neurol Ther. 2017 Jul;6(Suppl 1):1-4. doi: 10.1007/s40120-017-0068-6. Epub 2017 Jul 21. No abstract available.

Supplemental Content

Support Center